Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride + trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel + trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer | Publicación